Norway Women Bring Seaweed to Culinary Heights in Europe

Lofoten Seaweed co-founder Angelita Eriksen picks kelp from the icy Norwegian waters. Olivier MORIN / AFP
Lofoten Seaweed co-founder Angelita Eriksen picks kelp from the icy Norwegian waters. Olivier MORIN / AFP
TT

Norway Women Bring Seaweed to Culinary Heights in Europe

Lofoten Seaweed co-founder Angelita Eriksen picks kelp from the icy Norwegian waters. Olivier MORIN / AFP
Lofoten Seaweed co-founder Angelita Eriksen picks kelp from the icy Norwegian waters. Olivier MORIN / AFP

In the glacial waters of the Lofoten archipelago in Norway's far north, Angelita Eriksen uses a knife to cut a handful of seaweed that will soon end up in a fancy European eatery.
"We have the cleanest and clearest waters in the world. We're very lucky that we have this really important resource growing right outside our doorstep," Eriksen told AFP in a cabin on the shores of the northern Atlantic Ocean where the seaweed is laid out to dry.
"We want to show that to the world."
The daughter of a Norwegian fisherman, Eriksen joined forces with New Zealand-born Tamara Singer, whose Japanese mother served seaweed with almost every meal, to start the company Lofoten Seaweed -- specializing in harvesting and preparing seaweed for the food industry.
With the help of six others, they hand-pick 11 tons of seaweed a year, the snow-capped mountains plummeting into the sea behind them in a dramatic tableau.
It's a demanding and "physical job", said Eriksen.
The peak season runs from late April until June, but "we harvest the dulse, the nori and the sea truffle in the winter and fall".
"It can be quite cold, as we can stay out for about an hour along the shore", with lower legs and hands submerged in the chilly water.
By "late May, I'm actually sweating in my suit".
One time, she said, "I took my glove off and the steam was just rising up".
"It's physically hard but at the same time it's very meditative, or therapeutic in a way, to harvest," she says.
'Delicate'
Truffle seaweed, winged kelp, nori, dulse, sugar kelp, oarweed kelp: the pair focus on about 10 types of seaweed, long eaten in Japan and increasingly popular in Europe for their nutritional qualities.
The seaweed is sold locally or shipped to gourmet restaurants in Norway and the rest of Europe.
The two women organize workshops to teach chefs about the different varieties and the qualities of each type.
"Seaweeds are like vegetables, they have their own texture, taste and colors," says Singer.
She said it was a "huge surprise" how many European chefs had little or no knowledge of the different flavors and ways of preparing seaweed.
The duo have worked with Japanese chefs "who know exactly what to do, you don't have to tell them anything".
"It's just so natural for them. It's like giving a piece of fish to a North Norwegian," says Singer.
Some 20 kilometers (12 miles) away, chef Josh Wing has been serving the pair's products in his high-end restaurant Hattvika Lodge for about five years.
He is well versed and does not need to take part in their workshops anymore.
Wing is particularly fond of the dulse, a "very delicate purple seaweed", which he serves with local fish dishes or bread.
It "can provide a physical texture in a dish that you can't get from other products", he tells AFP.
To ensure that their business is sustainable, Eriksen and Singer have mapped and dated their harvest sites, as well as the volumes of each species, for the past four years.
"Our results show that the regrowth in recently-harvested patches is actually faster than anticipated, almost as if a harvest actually stimulates growth," says Singer.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”